CION Ameerpet
Precancer Explained · Reviewed by CION Oncologists · NABH Accredited
Hyperplasia Without Atypia — The Reassuring One
If your biopsy report says hyperplasia without atypia, you have the commoner and far less worrying of the two types — and it is worth being clear about that before you read anything else. Fewer than 5 in 100 women with this diagnosis develop endometrial cancer over 20 years, and a substantial proportion of cases resolve on their own or with hormone treatment. It is a benign condition caused by a hormone imbalance, it is treated with hormones rather than surgery, and a hysterectomy is not the first-line answer. Much of what you will find online about hyperplasia describes the other type. It does not describe you.
- The cells look normal — crowded glands, but no abnormal cells — that is what “without atypia” means
- Progression is uncommon — under 5 in 100 women over 20 years in long-term follow-up
- Hormones, not surgery — a hormone-releasing device is first-line in current guidance
- Repeat biopsy proves it worked — not the bleeding settling, which happens much sooner
17+
Cancer Specialists
on Panel
on Panel
35+
Centres
Across India
Across India
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
What the Report Is Telling You
The pathologist looked at your lining and answered two questions. The first was about the architecture: are the glands crowded and overgrown? The answer was yes — that is the hyperplasia. The second was about the cells themselves: do they look abnormal? The answer was no. That is the “without atypia”.
That second answer is the one that matters, and it changes everything:
- The tissue has not begun to look like a cancer. Atypia describes cells that have acquired abnormal features — enlarged, irregular nuclei with a changed appearance. Yours have not. The tissue is overgrown, not transformed.
- The risk of an undetected cancer is low. This matters because a biopsy samples only part of the lining. With atypia, a cancer is found alongside in a substantial minority of cases; without atypia, that concern is far smaller — which is why watching and treating is reasonable here and not there.
- Progression is uncommon and slow. Under 5 in 100 women over 20 years, and that figure describes untreated disease. Treatment interrupts it.
- Older reports may say it differently. “Simple hyperplasia” or “complex hyperplasia without atypia” are from the previous four-category system and both mean the same thing in current terms. What matters is the absence of atypia.
For the other type and how the two compare side by side, see endometrial hyperplasia and atypical hyperplasia.
Did You Know? A large majority of women with hyperplasia without atypia never develop cancer — and one reason the figure is so low is that this condition often reverses. Given a source of progesterone, an overgrown lining that has not acquired abnormal cells can simply return to normal. That is why treatment here is a hormone rather than an operation, and why it works: it is not suppressing something dangerous, it is supplying what was missing. What it cannot do is fix the underlying cause. If the weight, the anovulation or the unopposed oestrogen that produced the hyperplasia stays exactly as it was, the lining is being returned to the conditions that created it. Sources: RCOG / BSGE Green-top Guideline No. 67 on the management of endometrial hyperplasia; World Health Organization classification of tumours of female reproductive organs; NCCN Clinical Practice Guidelines in Oncology — Uterine Neoplasms.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
What Management Should Look Like
Guidance on this is reasonably clear, and it is worth knowing so that you can recognise a plan that departs from it.
| Step | What should happen |
|---|---|
| First-line treatment | Progestin therapy, and current guidance specifically favours a hormone-releasing intrauterine device over tablets — higher regression rates and better tolerated. Oral progestin where a device is unsuitable or declined. See progestin therapy. |
| Confirming it worked | Repeat endometrial sampling during treatment, continuing until consecutive normal results. Not judged by whether bleeding has settled, which usually happens months earlier. See follow-up and monitoring. |
| How long treatment continues | Longer than most women expect. Guidance supports keeping a hormone-releasing device in place for a prolonged period after regression, particularly where the underlying risk from weight or anovulation persists. |
| Treating the cause | Weight, blood sugar and hormone exposure produced this lining and will go on producing it. Addressing them is part of the treatment. See what causes hyperplasia. |
| When surgery is considered | Not first-line. Reserved for failure to regress on adequate treatment, hyperplasia that keeps returning, progression to atypia, or a woman who cannot undertake the surveillance that makes medical management safe. |
| What is never appropriate | Endometrial ablation. It destroys the lining rather than removing it for examination and leaves tissue that cannot be sampled afterwards — removing the ability to know whether the condition has resolved. |
If a hysterectomy has been recommended as the first response to hyperplasia without atypia, that is worth questioning. It is not what current guidance advises for this type, and the great majority of women are managed successfully with a hormone device and repeat sampling. There are legitimate reasons a surgeon might still advise it — failed treatment, other gynaecological problems, a woman who cannot attend follow-up — but they should be stated, not assumed.
Want a Second View on the Plan You Have Been Given?
Particularly if surgery was proposed. Bring the biopsy report and we will tell you plainly what guidance recommends for your type.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
This Type Is Treated With Hormones, Not an Operation
And in most women it clears — which is confirmed by a repeat biopsy rather than assumed.
The Part Where This Goes Wrong
Hyperplasia without atypia is a straightforward condition with an effective treatment, and the commonest way it is mishandled has nothing to do with the treatment at all.
Bleeding usually settles within a few months of starting a progestin. The woman feels well, the symptom that brought her in has gone, and the repeat biopsy appointment starts to feel unnecessary. She does not attend. Nobody chases it.
- Symptoms and histology are different things. The lining can still show hyperplasia after the bleeding has stopped. Treatment is judged on tissue, which is why guidance is explicit about sampling until consecutive normal results.
- The device can be expelled without you noticing. Particularly in the first months. If treatment is being delivered by a device that is no longer correctly placed, the lining is effectively untreated while everyone assumes otherwise.
- Recurrence is common where the cause has not changed. Which is precisely why treatment often continues well beyond the first clear result rather than stopping at it. See can hyperplasia come back.
- Bleeding that returns after settling is the signal to report. Early irregular spotting is expected. Bleeding that stops for months and then restarts is different, and it should be assessed rather than absorbed into the general expectation of irregularity.
If you have had treatment for hyperplasia and drifted out of follow-up, rebooking is straightforward and worth doing. The gap is what causes problems, not the missed appointment itself.
Diagnosed With This and Unsure of the Plan?
What treatment should be, how long it lasts, and when the repeat biopsies happen. All of it is worth knowing. The opinion is free.
What Caused It, and What to Do About That
Treating the lining without addressing what produced it is treating a consequence. These are the usual drivers.
Commonest
Excess Body Weight
Fat tissue produces oestrogen independently of the ovaries. The largest single driver, and the one where change makes most difference. See obesity and endometrial cancer.
Common
Cycles Without Ovulation
No egg released means no progesterone, so the lining grows unopposed. The mechanism in PCOS and in perimenopause.
Correctable
Oestrogen Without a Progestogen
HRT given as oestrogen alone to a woman with a uterus removes the brake entirely. The most directly fixable cause. See oestrogen-only HRT.
Metabolic
Diabetes and Insulin Resistance
Operate alongside the oestrogen pathway and are highly prevalent regionally. See diabetes and risk.
Treatment-related
Hormonal Breast Cancer Treatment
Some treatments act on the uterine lining in the opposite way to how they act on the breast. Bleeding, not routine scanning, is what triggers investigation.
Inherited
Lynch Syndrome
Worth considering where hyperplasia appears at a young age or alongside a family history of bowel and womb cancer. See Lynch syndrome.
Why This Deserves a Proper Plan Rather Than a Prescription
The treatment is simple. Proving it worked, and preventing it returning, is where care is usually lost.
Scan and biopsy in one visit
Follow-up you can actually keep
Slides reviewed, not just the summary line
45-minute consultations
Survivorship care that is actually offered
Decisions for healing, not billing
Take The Next Step
This Is the Type Most Likely to Simply Go Away
With the right treatment and a follow-up plan that someone is actually running.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Hyperplasia Without Atypia — Frequently Asked Questions
Is hyperplasia without atypia dangerous?
It is a benign condition and the risk of it becoming cancer is low. Long-term follow-up studies put progression to endometrial carcinoma at fewer than 5 in 100 women over 20 years, and a substantial proportion of cases regress spontaneously or with hormone treatment. It is worth being clear about this because much of what is written about endometrial hyperplasia online describes the other category — atypical hyperplasia — which behaves quite differently and is managed with surgery. If your report says "without atypia", the more alarming material does not describe your situation. What the diagnosis does require is treatment and, importantly, repeat biopsies to confirm the lining has cleared.
Will I need a hysterectomy?
Almost certainly not as a first step. Current guidance recommends progestin therapy as first-line treatment for hyperplasia without atypia, specifically favouring a hormone-releasing intrauterine device over tablets, with repeat endometrial sampling to confirm the lining has returned to normal. Hysterectomy is reserved for particular circumstances: failure to regress despite adequate treatment, hyperplasia that keeps returning, progression to atypia on a follow-up sample, or a woman who is unable to attend the surveillance that makes medical management safe. If surgery has been proposed as the immediate answer, it is reasonable to ask what specifically takes your case outside the standard pathway.
How will I know the treatment has worked?
By a repeat biopsy, not by the bleeding settling — and this distinction is the single most useful thing on this page. Bleeding typically improves within the first few months of progestin treatment, long before the histology is confirmed normal, and many women understandably interpret that as cure and stop attending. But the lining can still show hyperplasia after the symptom has resolved. Guidance is explicit that treatment is judged by repeat endometrial sampling, and that sampling continues until consecutive normal results are obtained — usually meaning samples taken across the first year rather than a single check.
Can hyperplasia without atypia come back?
Yes, and this is common enough to plan for rather than be surprised by. The reason is straightforward: hormone treatment clears the lining but does not change the hormonal environment that produced the overgrowth. If excess body weight, anovulatory cycles or unopposed oestrogen exposure remain unchanged, the lining is being returned to exactly the conditions that created the problem. This is why guidance supports keeping a hormone-releasing device in place for a prolonged period after regression rather than removing it as soon as the first clear result arrives, and why addressing the underlying cause is treated as part of the treatment rather than as general advice.
Is endometrial ablation an option instead?
No, and this is worth being firm about because ablation is offered for heavy bleeding in other contexts and can seem like an attractive alternative. Ablation destroys the lining rather than removing it, so the tissue cannot be examined, and it leaves behind pockets of endometrium that are very difficult to sample afterwards. In a woman with hyperplasia, that combination removes the ability to know whether the condition has resolved or progressed — which is precisely what the surveillance biopsies exist to establish. It is not an accepted treatment for endometrial hyperplasia of either type. If it has been suggested, ask for the reasoning.
Medical disclaimer: This page explains hyperplasia without atypia in general terms and is reviewed by a CION oncologist, following the World Health Organization classification, RCOG/BSGE Green-top Guideline No. 67, and current NCCN guidance. Figures quoted describe groups of women in long-term follow-up studies and do not predict what will happen to any individual. It is not an interpretation of your own biopsy report; management should be discussed with a specialist who has seen your pathology.